Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction ca... by Kang, Yoon-Koo, Prof, Chen, Li-Tzong, Prof, Ryu, Min-Hee, Prof, Oh, Do-Youn, Prof, Oh, Sang Cheul, MD, Chung, Hyun Cheol, Prof, Lee, Keun-Wook, Prof, Omori, Takeshi, MD, Shitara, Kohei, MD, Sakuramoto, Shinichi, Prof, Chung, Ik-Joo, Prof, Yamaguchi, Kensei, MD, Kato, Ken, MD, Sym, Sun Jin, Prof, Kadowaki, Shigenori, MD, Tsuji, Kunihiro, MD, Chen, Jen-Shi, MD, Bai, Li-Yuan, MD, Oh, Sung-Yong, MD, Choda, Yasuhiro, MD, Yasui, Hisateru, MD, Takeuchi, Kentaro, MSc, Hirashima, Yoshinori, MD, Hagihara, Shunsuke, MSc, Boku, Narikazu, MD

Get full text

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial by Catenacci, Daniel V T, MD, Kang, Yoon-Koo, Prof, Park, Haeseong, MD, Uronis, Hope E, MD, Lee, Keun-Wook, Prof, Ng, Matthew C H, MD, Enzinger, Peter C, MD, Park, Se Hoon, Prof, Gold, Philip J, MD, Lacy, Jill, Prof, Hochster, Howard S, Prof, Oh, Sang Cheul, Professor, Kim, Yeul Hong, Prof, Marrone, Kristen A, MD, Kelly, Ronan J, Prof, Juergens, Rosalyn A, MD, Kim, Jong Gwang, MD, Bendell, Johanna C, MD, Alcindor, Thierry, MD, Sym, Sun Jin, MD, Song, Eun-Kee, Prof, Chee, Cheng Ean, MD, Chao, Yee, Prof, Kim, Sunnie, MD, Lockhart, A Craig, Prof, Knutson, Keith L, Prof, Yen, Jennifer, PhD, Franovic, Aleksandra, PhD, Nordstrom, Jeffrey L, PhD, Li, Daner, MS, Wigginton, Jon, MD, Davidson-Moncada, Jan K, MD, Rosales, Minori Koshiji, MD, Bang, Yung-Jue, Prof

Get full text